Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

Cardiac resynchronization therapy (CRT) in heart failure--a model to assess the economic value of this new medical

¹OUTCOMES INTERNATIONAL, Basel, Switzerland. kurt.banz@outcomes.ch

Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research

|April 5, 2005

Summary

Cardiac resynchronization therapy (CRT) is a cost-effective treatment for heart failure, recouping costs through reduced hospitalizations. This European model helps assess CRT

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Exploratory cost-effectiveness analysis of cardiac resynchronization therapy with systematic device optimization vs. standard (non-systematic) optimization: a multinational economic evaluation.

Health economics review·2015

Same author

Evaluation of a possible predictor for Federal Joint Committee decisions on early benefit assessments according to the German act on the reform of the market for medicinal products.

Health policy (Amsterdam, Netherlands)·2014

Same author

Cost effectiveness of transcatheter aortic valve replacement compared to medical management in inoperable patients with severe aortic stenosis: Canadian analysis based on the PARTNER Trial Cohort B findings.

Journal of medical economics·2013

Same author

Comparison of treatment costs of grade 3/4 adverse events associated with erlotinib or pemetrexed maintenance therapy for patients with advanced non-small-cell lung cancer (NSCLC) in Germany, France, Italy, and Spain.

Lung cancer (Amsterdam, Netherlands)·2011

Same author

Economic evaluation of varicella vaccination in Swiss children and adolescents.

Human vaccines·2009

Same author

Prospective surveillance of varicella-zoster virus infections in an out-patient setting in Switzerland.

Human vaccines·2009

Area of Science:

Health Economics
Cardiology
Clinical Decision Analysis

Background:

Heart failure management involves optimizing pharmacological therapy (OPT).
Cardiac resynchronization therapy (CRT) offers an alternative or adjunctive treatment.
Assessing the clinical and economic value of CRT is crucial for healthcare decision-making.

Purpose of the Study:

To describe a comprehensive European model for evaluating clinical and economic outcomes of CRT versus OPT.
To provide a flexible framework adaptable to different European healthcare settings.
To inform economic appraisals and reimbursement decisions.

Main Methods:

A decision-analysis model incorporating literature data, expert opinion, and steering committee input.
Inclusion of direct medical and indirect costs, with outcomes calculated up to 5 years.

Related Experiment Videos

Utilized clinical trial data, expert opinions, health statistics, and tariff lists for a German economic appraisal.

Main Results:

The model demonstrates CRT as a cost-effective intervention in Germany.
CRT recoups 22% of its upfront cost within one year due to decreased hospitalizations.
Incremental cost per Quality-Adjusted Life-Year (QALY) gained is below common cost-effectiveness thresholds.

Conclusions:

The European CRT model is a valuable tool for assessing the economic value of CRT in heart failure patients.
Model-generated economic data can support decision-making, especially with the introduction of Diagnosis Related Group (DRG) based reimbursement.
CRT represents a cost-effective strategy with significant economic benefits in moderate to severe heart failure.